Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 3/2012

01-06-2012

18F-FDG positron emission tomography: potential utility in the assessment of Crohn’s disease

Author: Paul B. Shyn

Published in: Abdominal Radiology | Issue 3/2012

Login to get access

Abstract

Computed Tomography Enterography (CTE) and Magnetic Resonance Enterography (MRE) are currently the dominant imaging tests used in the assessment of patients with Crohn’s disease. More recently, the possibility of utilizing F-18 fluorodeoxyglucose (18F-FDG) Positron Emission Tomography (PET) or PET/CT has been explored in several preliminary studies. 18F-FDG PET appears to enable reliable detection of moderate to severe inflammation in bowel segments involved by Crohn’s disease. Perhaps more importantly, 18F-FDG PET has the potential to provide a noninvasive, quantitative measure of inflammation that dynamically reflects changes in Crohn’s disease activity. If 18F-FDG PET proves useful in monitoring responses to medical therapy within a few days of therapy initiation, an important new role for imaging in the management of patients with Crohn’s disease could emerge.
Literature
1.
2.
Loftus EV Jr, Schoenfeld P, Sandborn WJ (2002) The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 16:51–60PubMedCrossRef
3.
Silverstein MD, Loftus EV, Sandborn WJ, et al. (1999) Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterology 117:49–57PubMedCrossRef
4.
Michelassi F, Balestracci T, Chappell R, Block GE (1991) Primary and recurrent Crohn’s disease. Experience with 1379 patients. Ann Surg 214:230–238 (discussion 238–40)PubMedCrossRef
5.
Mekhjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK (1979) Clinical features and natural history of Crohn’s disease. Gastroenterology 77:898–906PubMed
6.
Rutgeerts P, Geboes K, Vantrappen G, et al. (1990) Predictability of the postoperative course of Crohn’s disease. Gastroenterology 99:956–963PubMed
7.
Van Assche G, Vermeire S, Rutgeerts P (2010) The potential for disease modification in Crohn’s disease. Nature reviews. Gastroenterol Hepatol 7:79–85
8.
Louis E, Collard A, Oger AF, et al. (2001) Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut 49:777–782PubMedCrossRef
9.
Guimaraes LS, Fidler JL, Fletcher JG, et al. (2010) Assessment of appropriateness of indications for CT enterography in younger patients. Inflamm Bowel Dis 16:226–232PubMed
10.
Rimola J, Rodriguez S, Garcia-Bosch O, et al. (2009) Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s disease. Gut 58:1113–1120PubMedCrossRef
11.
Lee SS, Kim AY, Yang SK, et al. (2009) Crohn disease of the small bowel: comparison of CT enterography, MR Enterography, and small-bowel follow-through as diagnostic techniques. Radiology 251:751–761PubMedCrossRef
12.
Booya F, Fletcher JG, Huprich JE, et al. (2006) Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography. Radiology 241:787–795PubMedCrossRef
13.
Bodily KD, Fletcher JG, Solem CA, et al. (2006) Crohn disease: mural attenuation and thickness at contrast-enhanced CT Enterography–correlation with endoscopic and histologic findings of inflammation. Radiology 238:505–516PubMedCrossRef
14.
Florie J, Wasser MN, Arts-Cieslik K, et al. (2006) Dynamic contrast-enhanced MRI of the bowel wall for assessment of disease activity in Crohn’s disease. AJR Am J Roentgenol 186:1384–1392PubMedCrossRef
15.
Punwani S, Rodriguez-Justo M, Bainbridge A, et al. (2009) Mural inflammation in Crohn disease: location-matched histologic validation of MR imaging features. Radiology 252:712–720PubMedCrossRef
16.
Sempere GA, Sanjuan VM, Chulia EM, et al. (2005) MRI evaluation of inflammatory activity in Crohn’s disease. AJR Am J Roentgenol 184:1829–1835PubMed
17.
D’Haens GR (2010) Top-down therapy for IBD: rationale and requisite evidence. Nature reviews. Gastroenterol Hepatol 7:86–92
18.
Cohen RD (2010) The pharmacoeconomics of biologic therapy for IBD. Nature reviews. Gastroenterol Hepatol 7:103–109
19.
Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD (2005) Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54:1121–1125PubMedCrossRef
20.
D’Haens G (2007) Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 56:725–732PubMedCrossRef
21.
Glaudemans AW, Maccioni F, Mansi L, Dierckx RA, Signore A (2010) Imaging of cell trafficking in Crohn’s disease. J Cell Physiol 223:562–571PubMed
22.
Gotthardt M, Bleeker-Rovers CP, Boerman OC, Oyen WJ (2010) Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med Off Publ Soc Nucl Med 51:1937–1949
23.
Neurath MF, Vehling D, Schunk K, et al. (2002) Noninvasive assessment of Crohn’s disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol 97:1978–1985PubMedCrossRef
24.
Lemberg DA, Issenman RM, Cawdron R, et al. (2005) Positron emission tomography in the investigation of pediatric inflammatory bowel disease. Inflamm Bowel Dis 11:733–738PubMedCrossRef
25.
Loffler M, Weckesser M, Franzius C, Schober O, Zimmer KP (2006) High diagnostic value of 18F-FDG-PET in pediatric patients with chronic inflammatory bowel disease. Ann N Y Acad Sci 1072:379–385PubMedCrossRef
26.
Meisner RS, Spier BJ, Einarsson S, et al. (2007) Pilot study using PET/CT as a novel, noninvasive assessment of disease activity in inflammatory bowel disease. Inflamm Bowel Dis 13:993–1000PubMedCrossRef
27.
Louis E, Ancion G, Colard A, et al. (2007) Noninvasive assessment of Crohn’s disease intestinal lesions with (18)F-FDG PET/CT. J Nucl Med Off Publ Soc Nucl Med 48:1053–1059
28.
Dabritz J, Jasper N, Loeffler M, Weckesser M, Foell D (2011) Noninvasive assessment of pediatric inflammatory bowel disease with (1)F-fluorodeoxyglucose-positron emission tomography and computed tomography. Eur J Gastroenterol Hepatol 23:81–89PubMedCrossRef
29.
Shyn PB, Mortele KJ, Britz-Cunningham SH, et al. (2010) Low-dose 18F-FDG PET/CT enterography: improving on CT enterography assessment of patients with Crohn disease. J Nucl Med Off Publ Soc Nucl Med 51:1841–1848
30.
Das CJ, Makharia G, Kumar R, et al. (2007) PET-CT enteroclysis: a new technique for evaluation of inflammatory diseases of the intestine. Eur J Nucl Med Mol Imag 34:2106–2114CrossRef
31.
Ahmadi A, Li Q, Muller K, et al. (2010) Diagnostic value of noninvasive combined fluorine-18 labeled fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography enterography in active Crohn’s disease. Inflamm Bowel Dis 16:974–981PubMed
32.
33.
Guyatt G, Mitchell A, Irvine EJ, et al. (1989) A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 96:804–810PubMed
34.
Vermeire S, Van Assche G, Rutgeerts P (2004) C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 10:661–665PubMedCrossRef
35.
Yanai H, Hanauer SB (2011) Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 106:685–698PubMedCrossRef
36.
Pellegrino D, Bonab AA, Dragotakes SC, et al. (2005) Inflammation and infection: imaging properties of 18F-FDG-labeled white blood cells versus 18F-FDG. J Nucl Med Off Publ Soc Nucl Med 46:1522–1530
37.
Spier BJ, Perlman SB, Jaskowiak CJ, Reichelderfer M (2010) PET/CT in the evaluation of inflammatory bowel disease: studies in patients before and after treatment. Mol Imag Biol Off Publ Acad Mol Imag 12:85–88
38.
Weber WA (2009) Assessing tumor response to therapy. J Nucl Med Off Publ Soc Nucl Med 50(Suppl 1):1S–10S
39.
Contractor KB, Aboagye EO (2009) Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med Off Publ Soc Nucl Med 50(Suppl 1):97S–105S
40.
Elzinga EH, van der Laken CJ, Comans EF, et al. (2011) 18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study. J Nucl Med Off Publ Soc Nucl Med 52:77–80
41.
Van Assche G, Geboes K, Rutgeerts P (2004) Medical therapy for Crohn’s disease strictures. Inflamm Bowel Dis 10:55–60PubMedCrossRef
42.
Jacene HA, Ginsburg P, Kwon J, et al. (2009) Prediction of the need for surgical intervention in obstructive Crohn’s disease by 18F-FDG PET/CT. J Nucl Med Off Publ Soc Nucl Med 50:1751–1759
43.
Sahni VA, Shyn PB (2010) Predicting the need for surgery in obstructive Crohn’s disease: how hot is PET/CT? Inflamm Bowel Dis 16:2182–2183PubMedCrossRef
44.
Burke JP, Mulsow JJ, O’Keane C, et al. (2007) Fibrogenesis in Crohn’s disease. Am J Gastroenterol 102:439–448PubMedCrossRef
45.
Borley NR, Mortensen NJ, Kettlewell MG, et al. (2001) Connective tissue changes in ileal Crohn’s disease: relationship to disease phenotype and ulcer-associated cell lineage. Dis Colon Rectum 44:388–396PubMedCrossRef
46.
Mettler FA Jr, Huda W, Yoshizumi TT, Mahesh M (2008) Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 248:254–263PubMedCrossRef
47.
Coakley FV, Gould R, Yeh BM, Arenson RL (2011) CT radiation dose: what can you do right now in your practice? AJR Am J Roentgenol 196:619–625PubMedCrossRef
48.
Flicek KT, Hara AK, Silva AC, et al. (2010) Reducing the radiation dose for CT colonography using adaptive statistical iterative reconstruction: a pilot study. AJR Am J Roentgenol 195:126–131PubMedCrossRef
49.
Yau YY, Chan WS, Tam YM, et al. (2005) Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error? J Nucl Med Off Publ Soc Nucl Med 46:283–291
50.
Rubin DT, Surma BL, Gavzy SJ, et al. (2009) Positron emission tomography (PET) used to image subclinical inflammation associated with ulcerative colitis (UC) in remission. Inflamm Bowel Dis 15:750–755PubMedCrossRef
Metadata
Title
18F-FDG positron emission tomography: potential utility in the assessment of Crohn’s disease
Author
Paul B. Shyn
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Abdominal Radiology / Issue 3/2012
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-011-9793-y

Other articles of this Issue 3/2012

Abdominal Radiology 3/2012 Go to the issue

OriginalPaper

Crohn’s disease: prevalence of intestinal and extraintestinal manifestations detected by computed tomography enterography with water enema

OriginalPaper

Small bowel adenocarcinoma in Crohn disease: CT-enterography features with pathological correlation

OriginalPaper

Prediction of the therapeutic effects of anticoagulation for recent portal vein thrombosis: a novel approach with contrast-enhanced ultrasound

OriginalPaper

Functional evaluation of cystic duct patency with Gd-EOB-DTPA MR imaging: an alternative to hepatobiliary scintigraphy for diagnosis of acute cholecystitis?

OriginalPaper

Non-tropical chyluria: CT diagnosis

OriginalPaper

Small bowel Crohn’s disease: MR enteroclysis and capsule endoscopy compared to balloon-assisted enteroscopy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits